secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-211867
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LeonaBio Q1 2026 net loss $32.9M ($1.73/share); cash burn $20.9M; ELAINE-3 enrollment target Q4 2026
--------------------------------------------------------------------------------

- Net loss of $32.9M ($1.73 per share) vs $9.1M ($2.34) in Q1 2025, driven by higher R&D spend.
- Cash, equivalents and investments $67.7M at March 31, 2026, down from $88.3M at Dec 31, 2025.
- R&D expenses $10.3M (up 139% YoY) due to Phase 3 ELAINE-3 lasofoxifene trial costs.
- Expects to complete enrollment of Phase 3 ELAINE-3 in Q4 2026; topline data 2H 2027.
- Appointed Fred Callori, Natalie Holles, Peter Silverman to Board; John Fluke Jr. retired.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000119312526211867/0001193125-26-211867-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000119312526211867/lona-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-211867

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer